Latest Us Expansion News

The Calmer Co. reports a significant operational turnaround in H2 FY25, with sales momentum building through July and August, driven by cost reductions and new product launches in the US market.

archTIS Limited has opened the retail component of a $17 million entitlement offer to support its acquisition of Spirion LLC’s assets, aiming to expand its US footprint and enhance its cybersecurity product suite.

Pure Hydrogen Corporation has signed a Letter of Intent with California's GTS Group to supply hydrogen-powered heavy vehicles, marking a strategic push into the North American market.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

xReality Group (XRG) reports a landmark FY25 with 36% revenue growth driven by its Operator XR platform and a major US law enforcement contract. The company’s strategic shift towards immersive training technology signals robust momentum into FY26.

Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Wiseway Group has delivered its strongest financial performance since listing, powered by a booming US division and a sharp focus on eCommerce imports across key markets.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

BetMakers Technology Group delivered a strong FY25 with a 5.6% half-on-half revenue growth and record profitability, while advancing its technology transformation and signing a strategic acquisition in Nevada.

Adveritas Limited reported a robust 89% increase in revenue to $7.84 million for FY25, driven by expanding customer contracts and product enhancements, while reducing its net loss by 39%. The company raised $8.5 million to fuel US expansion and new verticals.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.